5,238 Shares in Becton Dickinson and Co (BDX) Purchased by Tower View Investment Management & Research LLC

Tower View Investment Management & Research LLC bought a new position in shares of Becton Dickinson and Co (NYSE:BDX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,238 shares of the medical instruments supplier’s stock, valued at approximately $1,367,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Bank of Montreal Can raised its position in shares of Becton Dickinson and by 10.3% during the third quarter. Bank of Montreal Can now owns 800,214 shares of the medical instruments supplier’s stock valued at $208,856,000 after buying an additional 74,414 shares during the last quarter. Douglass Winthrop Advisors LLC raised its position in shares of Becton Dickinson and by 0.4% during the third quarter. Douglass Winthrop Advisors LLC now owns 270,473 shares of the medical instruments supplier’s stock valued at $70,593,000 after buying an additional 1,199 shares during the last quarter. Rathbone Brothers plc raised its position in shares of Becton Dickinson and by 0.3% during the third quarter. Rathbone Brothers plc now owns 203,172 shares of the medical instruments supplier’s stock valued at $53,028,000 after buying an additional 638 shares during the last quarter. Wendell David Associates Inc. raised its position in shares of Becton Dickinson and by 9.2% during the third quarter. Wendell David Associates Inc. now owns 26,186 shares of the medical instruments supplier’s stock valued at $6,835,000 after buying an additional 2,201 shares during the last quarter. Finally, Spearhead Capital Advisors LLC raised its position in shares of Becton Dickinson and by 1.4% during the third quarter. Spearhead Capital Advisors LLC now owns 15,525 shares of the medical instruments supplier’s stock valued at $3,887,000 after buying an additional 218 shares during the last quarter. Institutional investors own 92.51% of the company’s stock.

Shares of BDX stock traded up $4.13 on Friday, reaching $242.62. The company’s stock had a trading volume of 104,558 shares, compared to its average volume of 1,159,503. Becton Dickinson and Co has a 1 year low of $196.77 and a 1 year high of $265.87. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. The firm has a market cap of $69.83 billion, a PE ratio of 25.58, a price-to-earnings-growth ratio of 1.78 and a beta of 1.11.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.86 by $0.05. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The firm had revenue of $4.28 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same period last year, the firm posted $2.46 earnings per share. Becton Dickinson and’s revenue for the quarter was up 41.0% compared to the same quarter last year. On average, equities analysts predict that Becton Dickinson and Co will post 11.01 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 28th. Investors of record on Friday, September 7th were issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.24%. The ex-dividend date of this dividend was Thursday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 31.65%.

Several research firms have recently issued reports on BDX. Citigroup lifted their price objective on shares of Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Royal Bank of Canada reiterated a “hold” rating and set a $248.00 price objective on shares of Becton Dickinson and in a research report on Friday, August 3rd. JPMorgan Chase & Co. upgraded shares of Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective on the stock in a research report on Thursday, June 21st. ValuEngine upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Finally, Morgan Stanley lifted their price objective on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research report on Thursday, October 4th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $253.79.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Story: Moving Average (MA)

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply